News & Updates
Filter by Specialty:
Can rosuvastatin protect against chemo-induced cardiotoxicity in HER2+ breast cancer?
Use of rosuvastatin is associated with a significantly lower decline in left ventricular ejection fraction (LVEF) and lower serum levels of cardiotoxicity-associated biomarkers in newly diagnosed HER2-positive breast cancer patients treated with anthracycline-based chemotherapy followed by trastuzumab, according to the results of a prospective, randomized, controlled, parallel study.
Can rosuvastatin protect against chemo-induced cardiotoxicity in HER2+ breast cancer?
22 Jul 2024
Over-the-counter supplement touted for improving walking distance in PAD
Nicotinamide riboside supplements show a signal of benefit for helping patients with lower extremity peripheral arterial disease (PAD) walk more
Over-the-counter supplement touted for improving walking distance in PAD
21 Jul 2024
Wearables on par with conventional tools for cardiac monitoring
Electrocardiogram (ECG)- and photoplethysmography (PPG)-based wearable devices demonstrate effectiveness for paroxysmal atrial fibrillation (AF) detection following cryptogenic stroke or embolic stroke of undetermined source (ESUS) similar to that of conventional management, results of a Singapore study have shown.